Introduction
Suppression of Rb and p53 regulated cell cycle checkpoints occurs in most human tumors and both the Rb and p53 tumor suppressor proteins are targeted by the transforming proteins of DNA tumor viruses (Weinberg, 1995; Sherr and Roberts, 1995) . In the case of adenovirus, the E1A and E1B (55 kD but not 19 kD) proteins physically associate with RB and p53 proteins respectively. Recent evidence has suggested that other adenoviral proteins such as the E4orf6 may target p53 (Dobner et al., 1996) , and that E1A may target other cell cycle inhibitors such as p27
Kipl (Mal et al., 1996) or p21 WAF1/CIP1 (Missero et al., 1995) . Although Adenovirus E1A can immortalize rodent cells, for ecient transformation E1B is required to inhibit cell death induced by E1A (see White, 1995 for review) . The E1B region encodes a 19 kD and a 55 kD protein, each with the capacity to cooperate with E1A in transforming cells (White and Cipriani, 1990; Barker and Berk, 1987; Bernards et al., 1986; McLorie et al., 1991) . The 55 kD protein has been found to interact with p53 (Yew and Berk, 1992) whereas the 19 kD protein interacts with the death promoting Bax protein (Han et al., 1996) resulting in the inhibition of apoptosis. E1A encodes two mRNA species, 13S and 12S, which are translated into 289-and 243-amino acid proteins respectively. These proteins dier by 46 amino acids corresponding to the conserved region #3 (CR3), which encodes a transactivation domain (Moran and Mathews, 1987) . The 243-amino acid 12S E1A protein contains the sequences necessary for rodent cell transformation, i.e. the transactivation function of E1A is not required (Haley et al., 1984) . There are three regions in the 12S E1A protein which are required for transformation: (1) the nonconserved amino-terminus (aa 2 to 24), (2) the conserved region #1 (CR1; aa 40 to 80) and (3) the conserved region #2 (CR2; aa 120 to 140) (see Bayley and Mymryk, 1994 for review). These regions of E1A interact with two sets of cellular proteins: (1) the p300/CBP family of transcriptional co-activators, which bind to the Nterminus and CR1 of E1A and (2) the Rb family, which bind to CR1 and CR2. These interactions of E1A are thought to in¯uence functionally distinct growth-regulatory pathways which contribute additively to transformation (Moran, 1993) . For cellular transformation both the Rb-and p300/CBP-interacting domains of E1A are required, while either domain is sucient for induction of DNA synthesis (Howe et al., 1990; Wang et al., 1991 Wang et al., , 1993 . The mechanism by which the Rb-binding region of E1A permits unscheduled DNA synthesis involves binding to Rb family members thereby releasing the E2F family of transcription factors (Bagchi et al., 1990; Raychaudhuri et al., 1991; Helin et al., 1992; Kaelin et al., 1992) . However the role of the p300/CBP-binding region of E1A in either cell cycle deregulation or cellular transformation is much less clear.
While investigating E1A's eect on p21 expression, we found evidence that E1A could inhibit p53-dependent transcription. While this manuscript was under review, similar results were independently reported (Steegenga et al., 1996) . We focused on understanding the mechanism of the repression of p53-mediated transcription by E1A, the structural requirements within each protein for this repression and the outcome with respect to p53-dependent growth arrest following Adenovirus infection.
We found that the p300/CBP-binding domain of E1A inhibits transcription by p53 through eects on its transactivation domain. The ability of E1A to inhibit p53-mediated transactivation was correlated with its ability to overcome p53-dependent growth arrest. Additional experiments investigated the role of the p300/CBP-and Rb-interacting region of E1A with respect to stabilization of p53 protein. E1A is well known to stabilize p53 protein (Lowe and Ruley, 1993) , but the structural requirements within E1A and the consequences with respect to p53 function are less well understood. The present studies reveal increased p53 protein levels in cells expressing E1A lacking the p300/CBP-interacting region, thus providing a clue that stabilization of p53 and repression of p53-dependent transcription may be dissociated. Our ®ndings suggest that one mechanism by which the p300/CBP-binding domain of E1A deregulates the cell cycle may involve suppression of p53-mediated transcription and checkpoint control.
Results

E1A inhibits p53-mediated transcriptional activation
E1A has been recently reported to inhibit p53-independent p21 expression during keratinocyte differentiation (Missero et al., 1995) . While investigating this phenomenon in SW480 human colon cancer cells, we found that E1A inhibited p53-dependent transcription from the p21-promoter as well as from another p53-speci®c reporter plasmid (Figure 1a, b and c) . These results suggested that E1A could inhibit p53-dependent transcription. To further examine the speci®city of this inhibition, we showed that an N-terminus deletion mutant of E1A could not inhibit p53 activation of either the p21-promoter (Figure 1b) or PG13CAT (Figure 1c) . The PG13-CAT reporter was used as a positive control for p53-mediated transcription. The promoter in this reporter contains 13 tandem copies of an endogenous p53 DNA-binding site cloned upstream of a polyoma basal promoter; transcription from this 1 2 3 4 1 2 3 WWP-CAT PG13-CAT p53 12S E1A w.t. 12S E1A(dl 2-36)
(kDa) E1 A Figure 1 Eect of E1A on p53-mediated transactivation. (a, b, c) SW480 human colon cancer cells were transfected with lmg of either WWP-CAT (a, b) or PG13-CAT (c) reporter plasmids and, where indicated by`+', wild-type p53 expression plasmid (pCEP4-p53-wt; 3 mg), wild-type 12S E1A expression plasmid (3 mg), or N-terminus deletion derivative (dl 2-36; 3 mg). Lysates were prepared and analysed for CAT reporter activity at 20 h following transfection as described in Materials and methods. pUC18 plasmid DNA was added as required to keep the total DNA amount per transfection at 7 mg. (d) SW480 cells were transfected, as indicated, with the p53-speci®c reporter (PG13-Luc; 1 mg), wild-type p53 expression plasmid (pCEP4-p53-wt; 1 mg) and increasing amounts of the 12S E1A wt expression plasmid (amounts as indicated; mg). Luciferase activity was measured at 20 h following transfection as described in Materials and methods. pUC18 plasmid DNA was added as required to keep the total DNA amount per transfection at 7 mg. (e) Immunoblot of transfected SW480 cell lysates (transfections corresponding to (b) using anti-adenoviral type 5 E1A monoclonal antibody. (f) SW480 cells were transfected, as indicated, with a CMV-driven b-galactosidase reporter plasmid (pCMV b-Gal; 1 mg), wild-type p53 expression plasmid (pCEP4-p53-wt; 1 mg) and increasing amounts of E1A (as indicated) as described under (d). b-galactosidase activity was determined as described in Materials and methods E1A inhibition of p53/p21 function K Somasundaram and WS El-Deiry promoter is dependent upon the presence of wt p53 protein (Kern et al., 1992) . Both the wild-type and mutant E1A proteins were detected in E1A-transfected SW480 cells (Figure 1e ). This inhibition of transcription was dependent on the dose of E1A ( Figure 1d ) and was not observed with CMV-promoter driven transcription (Figure 1f ). These results suggested that Adenovirus E1A could inhibit p53-dependent transcription and that the N-terminus region was required for this repression.
E1A does not inhibit sequence-speci®c DNA-binding by p53
Since p53 activates transcription upon binding to speci®c DNA sequences, we next determined if the E1A inhibition of p53-mediated transactivation was due to inhibition of DNA binding. We investigated the eect of E1A on sequence-speci®c DNA-binding since this is the ®rst step and absolutely required for transactivation by p53 . . These results indicated that the inhibitory eects of E1A on p53-dependent transcription were not mediated through inhibition of sequence-speci®c DNA-binding by p53.
E1A targets the transactivation domain of p53
In the absence of inhibition of sequence-speci®c DNA binding, E1A could inhibit p53-dependent transcription through eects on p53's transactivation domain. To examine this possibility, we studied the eect of E1A on transactivation of a yeast Gal4 DNA-binding site-CAT reporter gene by the yeast Gal4 DNA-binding domain fused to p53's transactivation domain (Gal4-p53 (aa 1 ± 42) ( Figure 3 ). We subcloned the DNAcassette encoding the fusion proteins downstream of a CMV immediate early promoter since it is known that the SV40 early promoter, present upstream of the Gal4-p53 fusions in the parent vectors, is inhibited by E1A (Velcich and Zi, 1985) . Figure 3a shows that E1A inhibited transcriptional activity of the Gal4-p53 (aa 1 ± 42) fusion protein (compare lanes 5 vs 6, 7 and Figure 2 Eect of E1A on DNA binding by p53. (a) Electrophoretic mobility shift assays were performed using nuclear extracts derived from SW480 cancer cells transfected with wt p53 and wt E1A expression plasmids (as indicated). All reactions were carried out in the presence of p53 carboxy-terminal-speci®c antibody 421 (Hupp et al., 1992) . Mobility shifts shown in lanes 4 and 5, 6 and 7, or 9 and 10 represent duplicate experiments, respectively. (b) Control EMSA was done using nuclear extract derived from wt p53 transfected SW480 cells with pAB421 antibody and/or speci®c or nonspeci®c competitor oligonucleotide as indicated. Open arrow indicates the p53:DNA complex whereas the ®lled arrow indicates the supershifted p53:DNA complex by anti-p53 antibody. Binding conditions were as described in Materials and methods 8). As a control for the speci®city of E1A inhibition of p53's transactivation domain we determined the eect of E1A on transactivation by another heterologous fusion containing the yeast Gal4 DNA binding domain fused to the activation domain of herpes simplex virus transcription activator VP16. E1A did not inhibit transcription from a Gal4-VP16 fusion ( Figure 3a , lanes 9 and 10). Additional experiments revealed that E1A mutants lacking the ability to interact with p300 or CBP did not eciently inhibit transcriptional activation by p53 ( Figure 3b ). These results demonstrated that E1A speci®cally inhibits the transactivation domain of p53 and that the p300/CBP-binding region of E1A was required for this inhibition.
E1A's inhibition of p53-dependent cell cycle arrest following chemotherapy correlates with its ability to inhibit p53-mediated transactivation of p21
Repression of p53-dependent p21 induction might provide an alternative pathway by which adenovirus deregulates the cell cycle machinery. This is of particular interest since the p300/CBP-interacting domain of E1A inhibits p53-dependent transactivation (Figures 1 and 3) . Absence of p21 in a situation where p53 is induced in vivo, i.e. following DNA damage or adenoviral infection, might be expected to permit DNA synthesis despite p53 activation. In order to investigate this possibility, we evaluated the eect of adenoviral E1A on p53 and p21 expression levels in H460 human lung cancer cells following treatment with the chemotherapeutic agent adriamycin (Figure 4) . We used E1B
(7) adenovirus strains since the E1B 55 kD protein is known to inhibit p53's function as a transcription factor.
As expected, in the absence of adriamycin ( Figure  4a, b) , little or no p53 or p21 protein expression was detected in H460 lung cancer cells (Wu and El-Deiry, 1996) . Treatment of H460 cells with adriamycin led to accumulation of high levels of both p53 and p21 in the nuclei (Figure 4c, d) . However when the cells were infected with E1B (7) adenovirus expressing wt. E1A (Figure 4e, f) , the cells expressed high levels of p53 protein but failed to upregulate p21 protein expression. H460 cells treated with adriamycin and infected with the E1B (7) /E1A (7) adenovirus (Figure 4g , h) accumulated both p53 and p21 at levels similar to uninfected cells treated with adriamycin (c, d).
In order to correlate the immunohistochemical data with eects on cell cycle progression, we measured [ 3 H]thymidine incorporation in the H460 cells under the same conditions (Figure 4i ). E1A-expressing adenovirus inhibited the DNA damage induced cell cycle arrest, i.e. the cells continued to synthesize DNA despite the presence of DNA damage, whereas the E1A (7) adenovirus strain had little or no eect on inhibition of thymidine incorporation following chemotherapy. These results correlated the inhibition of p21-induction with S-phase progression in adenovirus infected cells. Similar results were obtained with another DNA damaging agent etoposide (Figure 4j ). Additional experiments (Figure 7 ; below) indicated that RB binding by E1A was not required for deregulation of this p53-mediated checkpoint by E1A.
Using electrophoretic mobility shift assays (EMSA), we con®rmed that sequence-speci®c DNA binding by p53 was not inhibited by E1A in the H460 cells ( Figure 5 ). As shown above in E1A transfected SW480 cells (Figure 2 ), adenovirus (E1A expressing) infection of H460 cells also did not inhibit the binding of p53 protein to its consensus site from the p21 promoter ( Figure 5 ). E1A-expressing adenovirus, presumably through stabilization of p53 protein enhanced sequence-speci®c DNA-binding by p53, either in the presence (Figure 5a Thus, p53 stabilized in response to the expression of E1A protein either in presence or absence of DNA damage eciently bound to its consensus DNAbinding site.
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Figure 3 Eect of E1A on the transactivation domain of p53. (a) SW480 cells were transfected with yeast Gal4 DNA binding sitereporter plasmid (pG5E1bCAT; 1 mg), and the indicated amounts (mg) of pCEP4-Gal4-p53 (aa 1 ± 42), pCEP4-Gal4-VP16 and 12S E1A wt. The GAL4-VP16 transfections in lanes 9, 10 were carried out separately from the transfections in lanes 1 ± 8, so the % CAT conversion is not directly comparable. Lysates were prepared and CAT assays were performed as described in Materials and methods. (b) SW480 cells transfected with yeast Gal4 DNA binding site-reporter plasmid (pG5E1bCAT; 1 mg), and pCEP4-Gal4-p53 (aa 1 ± 42) (2 mg), and as indicated, with 0.25 mg of either wt or various mutants of 12S E1A plasmid. pUC18 plasmid DNA was added as required to keep the total DNA amount per transfection at 7 mg. The activity of Gal4-p53 (aa 1 ± 42) was kept as 100%.
CAT assays were performed at 20 h following transfection as described in Materials and methods
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Dissociation of p53-stabilization vs repression of p53-mediated transactivation by E1A
It is well known that expression of 12S E1A leads to the stabilization of p53 protein in rat embryo ®broblasts (Lowe and Ruley, 1993) . We observed similar stabilization of p53 protein in H460 lung cancer cells (Figure 6 ). Because our experiments suggested that inhibition of p53-mediated transactivation by E1A required its p300/CBP-binding region, we investigated the eects of this region on p53 stabilization vs repression of transcription. Interestingly, we found that the p300/CBP-binding region of E1A was not required for p53 stabilization ( Figure 6 ). Such mutants stabilized p53 and the stabilized p53 was capable of p21 induction (Figure 6g, h and k, l) . The results suggested a dissociation between p53 stabilization and inhibition of p53-mediated transactivation. p53 (a, c, e, g ) or p21
DNA Synthesis
WAF1/CIP1 expression (b, d, f, h) using immunohistochemical methods, or analysed for progression into S-phase (i, j) by determining thymidine incorporation into newly synthesized DNA as described in Materials and methods E1A inhibition of p53/p21 function K Somasundaram and WS El-Deiry Thus, the p300/CBP-binding region of E1A, required for inhibition of p53-mediated transactivation, was not required for p53 stabilization. The inhibition of p53-mediated transactivation by the p300/CBP-binding region of E1A may be essential for E1A mediated transformation, because the p53 stabilized by E1A would otherwise suppress DNA synthesis by inducing p21, leading to growth arrest.
Adenovirus expressing E1A defective for p300/CBPbinding was a less potent inducer of DNA synthesis following DNA damage as compared with E1A defective for Rb binding
We compared the eects of adenovirus expressing various E1A mutants on p53-dependent transcription and cell cycle progression following DNA damage ( Figure 7 ). As expected, E1A mutants lacking the capacity to interact with p300 or CBP (dl n.ter and dl CR1) failed to suppress either p21 or MDM2 expression levels (Figure 7d and e) and were poor inducers of DNA synthesis following DNA damage (Figure 7a lanes 4, 6 vs  2) . The phosphorylation status of Rb was correlated with the extent of new DNA synthesis (Figure 7b vs a) . Surprisingly, a mutant of E1A incapable of binding to Rb (dl CR2) successfully permitted DNA synthesis in the presence of chemotherapy, in a manner similar to wildtype E1A (Figure 7a lane 5 vs 3) . We con®rmed that Rb protein failed to associate with this E1A mutant, but did associate with wild-type E1A protein (data not shown). Neither Rb nor CDK2 protein levels were signi®cantly altered by the adenovirus infection and chemotherapy. E1A protein expression was con®rmed in virus infected H460 cells (Figure 7g ). These observations support the hypothesis that E1A may override p53-activated checkpoint control through a mechanism independent of direct E1A-Rb complex formation, possibly through suppression of p53-dependent p21 induction. This function of E1A requires its p300/CBP-binding domain.
Functional interaction between p300/CBP and p53 in transcriptional activation
We found no evidence for a physical association between p53 and E1A proteins in vivo (data not shown). Therefore, in order to determine if there is a functional interaction, we studied eects of the E1A associated transcriptional co-activators p300 and CBP on the E1A-mediated repression of p53.
In co-transfection experiments using the p53-speci®c reporter PG13-Luc, we found that the E1A-associated co-activator CBP was capable of relieving the E1A-mediated repression of p53 very eciently (Figure 8a , compare lane 5 with lane 3) and in a dose dependent manner (Figure 8b ). p300 appeared less ecient at relieving repression of p53-mediated transactivation (Figure 8a, lane 4 vs 3) . These results suggested the possibility that the E1A-associated proteins, CBP and p300, may act as co-activators in p53-mediated transcription, although we found no evidence for stimulation of p53-dependent transcription in the absence of E1A (data not shown). Additional experiments demonstrated that CBP was capable of relieving E1A-mediated repression of transcriptional activation by the Gal4-p53 fusion protein (Figure 8c ).
Discussion
We found that Adenovirus E1A oncoprotein is a potent inhibitor of the transactivation function of the p53 tumor suppressor protein. The p300/CBP-interacting region of E1A, which is required for cellular transformation, was required for inhibition of p53-dependent gene expression, but was not required for the p53 stabilization that occurs in the presence of E1A. E1A lacking the capacity for p300-and CBPbinding stabilized p53 protein and was permissive for p53-dependent gene expression. On the other hand, E1A containing the p300/CBP-interacting domain and lacking the capacity for Rb-binding also stabilized p53 protein but repressed p53-dependent gene expression. Inhibition of p53-dependent p21 expression by E1A was correlated with suppression of cell cycle arrest following DNA damage. The p300/CBP-binding region of E1A targeted the transactivation domain of p53 while the sequence-speci®c DNA binding by p53 was not aected. There appeared to be no direct interaction between E1A and p53, but overexpression of either CBP or p300 relieved E1A's repressive eect on p53-speci®c transactivation.
The results support a novel mechanism for cell cycle deregulation by E1A. By suppressing transcriptional activation by p53, which would be expected to increase
Figure 5 DNA binding by p53 following adenoviral infection and exposure to chemotherapy. Electrophoretic mobility shift analysis for p53 was performed using nuclear extracts from H460 cells treated with adriamycin and infected with dierent adenoviruses as indicated. Lane 7 shows the (positive control) supershift observed when 100 ng of Baculovirus-expressed wildtype p53 was incubated with the labeled DNA probe and anti-p53 antibody. EMSA experiments were carried out as described in Materials and methods E1A inhibition of p53/p21 function K Somasundaram and WS El-Deiry upon p53 stabilization by E1A, critical cell cycle checkpoints are bypassed. The inhibition of p53-dependent p21 induction by E1A not only relieves a block at the G l /S boundary through p21's cyclin-CDKinhibitory eects, but also relieves a block during DNA replication through p21's interaction with PCNA and its eect on processive DNA synthesis (Waga et al., 1994) .
It has recently been reported that E1A could inhibit p53-independent p21 expression in dierentiating keratinocytes (Missero et al., 1995) . Inhibition of p21 expression by E1A was correlated with inhibition of dierentiation. Taken together with the present results and the work by Steegenga et al. (1996) and Missero et al. (1995) , it is likely that E1A inhibits both p53-dependent and p53-independent expression of p21. E1A also Ad-E1A p53 p21 -null w.t.
dl N.ter dl CR2 dl CR1 Figure 6 Dissociation of p53 stabilization vs repression of p53 mediated transactivation by E1A. H460 human lung cancer cells were either mock infected (a, b) or infected with Ad-E1A (null) (c, d), Ad-E1A (wt) (e, f), Ad-E1A (dl N-ter) (g, h), Ad-E1A (dl CR2) (i, j), Ad-E1A (dl CR1) (k, l) as described in Materials and methods. Cells were ®xed 24 h after the virus infection and analysed for either p53 (a, c, e, g, i, k) or p21 WAF1/CIP1 (b, d, f, h, j, l) protein expression using immunohistochemical methods as described in Materials and methods inhibits the function of the p27 cell cycle inhibitor in TGFb-treated cells (Mal et al., 1996) . E1A can therefore deregulate cell cycle control through multiple mechanisms impacting on the function of cyclin-CDK's and Sphase progression. The eect of E1A's p300/CBPinteracting domain on p53-dependent gene expression suggests a mechanism to explain why this domain may be required for transformation.
A previous study could not attribute an inhibitory eect of Ad5 on p21 expression to E1A (Spitkovsky et al., 1995) . Ad5 infection of human diploid ®broblasts inhibited p21 mRNA expression, whereas infection with a mutant adenovirus that lacks E1B and expresses E1A with altered migration (dl 313) allowed p21 expression. Interestingly, neither Ad5 nor dl 313 were able to overcome the transcriptional activity of exogenous murine temperature sensitive p53 at the permissive temperature. Although the E1A expressed by the dl 313 mutant was assumed to be wild-type, no explanation was given for its altered migration in the Western analysis following infection. Thus we could not conclude that the E1A protein expressed by dl 313 was wild-type. Alternatively the dierences may be due to dierences between cell lines used in Spitkovsky et al. and the present studies. Another recent study found that p21 mRNA was expressed in E1A-expressing BRK cells, suggesting that p21 expression may not be inhibited by E1A (Sabbatini et al., 1995a, b) . However, there was no direct comparison of p53 eects in cells which expressed E1A vs cells which did not express E1A.
Many previous studies have demonstrated a requirement of p53 in apoptosis induction by E1A (Debbas and White, 1993; Sabbatini et al., 1995a; Teodoro et al., 1995) . Recent experiments showed that apoptosis by E1A 12S protein was p53-dependent while p53-independent apoptosis occurred following E1A 13S protein expression (Teodoro et al., 1995) . This study suggested that unknown transcriptional targets of 13S E1A may play a role in apoptosis. However another study found a relationship between 13S E1A protein and transcriptional repression by p53 (Horikoshi et al., 1995) . Other studies have demonstrated that p53-mediated apoptosis could inhibit transformation by E1A and that inhibition of p53-dependent apoptosis is required for ecient transformation by E1A (Hansen et al., 1995; Sabbatini et al., 1995b) . Transcriptional activation by p53 has been found to be important for apoptosis following E1A expression (Sabbatini et al., 1995a) , and transactivation de®cient mutants were less capable to suppress E1A/ras mediated transformation (Mayr et al., 1995) . Our results demonstrating a loss of p53-dependent p21 expression by E1A ®t well with recent data suggesting that p21 expression may protect cells against apoptosis (Gorospe et al., 1996; Wang and Walsh, 1996; Polyak et al., 1996) . It is possible that the inhibition of p21 expression by E1A, while permitting DNA synthesis and cell cycle progression, may result in a loss of a protective signal against apoptosis. Such a scenario may explain why additional Adenovirus proteins may be required to inhibit apoptosis to eciently transform cells.
Our ®ndings suggest a novel pathway through which the p300/CBP-interacting region of E1A deregulates cell cycle control. Inhibition of p53-mediated transactivation of p21 allows E1A to suppress important cell cycle checkpoints, independent of its ability to interact with and inhibit Rb function. Thus, like SV40 large Tantigen, E1A targets a function of both Rb and p53. The ability of E1A to suppress p53-mediated transcription may be necessary (but not sucient) for transformation, whereas E1A-induced apoptosis (possibly through p53 stabilization in the absence of high p21 expression) must be suppressed in order to achieve a fully transformed state.
Materials and methods
Plasmids
The p53-speci®c reporter plasmids PG13-CAT (Kern et al., 1992) , 1993) , and the wt p53 expression plasmid pCEP4-p53 wt (El-Deiry et al., 1993) were provided by Dr B Vogelstein (Johns Hopkins Univ). The 12S E1A wt, 12S E1A (del 2 ± 36) expression plasmids and E1A.CXdl (del 121 ± 150) (Wang et al., 1993) were provided by Dr E Moran (Fels Inst of Cancer Res.). E1A.CXdl has a complete CR2 deletion and a partial CR3 deletion and because the partial CR3 deletion inactivates its transactivation function, the derivatives of E1A.CXdl behave as 12S E1A phenotypically (Wang et al., 1991) . This mutant is referred to here as dl CR2. The p300 expression plasmid (Eckner et al., 1994) was provided by Dr R Eckner (Dana Farber Cancer Inst).
The CBP expression plasmid pRc/RSV-CBP (Chrivia et al., 1993) was a gift from Dr RH Goodman (Oregon Health Sciences Univ). Plasmids containing fusions of the yeast Gal4 DNA binding domain fused to the p53 transcription activation domain (amino acids 1 ± 42), Gal4-p53 fusion expression plasmid (Gal4-p53 (aa 1 ± 42); Unger et al., 1992) , and the Gal4-DNA binding site reporter plasmid (pG5E1bCAT; Lillie and Green, 1989) were provided by Dr J Minna (University of Texas Southwestern Medical Center). Gal4-p53 (aa 1 ± 42) contains ®rst 42 amino acids of p53 fused to yeast Gal4 DNA binding domain and is expressed from the SV40 early promoter. A HindIII/BclI fragment carrying the Gal4- Figure 8 Eect of E1A-associated CBP and p300 on E1A-mediated repression of p53-mediated transcription. (a) SW480 human colon cancer cells were transfected with 1 mg of PG13-Luc reporter plasmid and 1 mg of p53 wt, 1.5 mg of 12S E1A wt, 5 mg of p300 wt and 5 mg of CBP wt plasmids as indicated. pUC18 plasmid DNA was added as required to maintain the total DNA amount per transfection constant at 7.5 mg. Luciferase assays were performed as described in Materials and methods. (b) SW480 cells were transfected with indicated amounts of PG13-Luc, P53 wt, 12S E1A wt, and CBP wt pUC18 plasmid DNA was added as required to maintain the total DNA amount per transfection at 7.5 mg. Luciferase assays were performed as described in Materials and methods. (c) SW480 cells were transfected with yeast Gal4 DNA binding site-CAT reporter plasmid (pG5E1bCAT; 1 mg), the Gal4 DNA-binding domain-p53 fusion expression plasmid (pCEP4-Gal4-p53 (aa 1 ± 42); 2 mg), E1A-wt (3 mg), and CBP (4 mg) as indicated (+). pUC18 plasmid was included to maintain the total amount of transfected DNA in this experiment at 10 mg. CAT assays were performed at 20 h following transfection as described in Materials and methods. CAT activity is expressed as % of control (100% = CAT reporter activity observed in the absence of either E1A or CBP; lane 1), based on phosphorimager quantitations p53 fusion was subcloned into HindIII/BamHI cut pCEP4 (Invitrogen). The Gal4-VP16 fusion (Lillie and Green, 1989) was cloned as a HindIII fragment into the HindIII site of pCEP4.
Cell lines, transfections, and reporter assays
The wild-type p53-expressing human non-small cell lung cancer cell line H460, a gift from Dr SB Baylin (Johns Hopkins Univ), was maintained in culture as previously described (Wu and El-Deiry, 1996) . The mutant p53-expressing human colon cancer cell line SW480 was obtained from the Cell Center at the University of Pennsylvania and passaged as previously described (Zeng and El-Deiry, 1996) . Transfection of SW480 cells was carried out, using the lipofectin reagent (Gibco-BRL), as previously described (El-Deiry et al., 1993) . Chloramphenicol acetyl transferase (CAT) assays were performed as previously described (Kern et al., 1992) . Luciferase and bgalactosidase assays were performed as previously described (Zeng and El-Deiry, 1996; Oliner et al., 1993) .
Adenoviral reagents and infections
The following adenoviruses used in this study were generously provided by Dr ST Bayley at McMaster University (Shepherd et al., 1993; Mymryk et al., 1994) : (1) Ad5 dl 520 E1B 7 lacks E1B but expresses wild-type 12S E1A only and is referred to as Ad-E1A-(wt).
(2) Ad5 dl 520 E1B 7 /1101 lacks E1B and expresses 12S E1A lacking amino acids 14 ± 25 which is required for binding to p300 or CBP and is referred to as Ad-E1A-(dl N.ter). (3) Ad5 dl 520 E1B 7 /1108 lacks E1B and expresses 12S E1A lacking amino acids 124 ± 127 which is required for binding to Rb and is referred to as Ad-E1A-(dl CR2). (4) Ad5 dl 520 E1B 7 /1143 lacks E1B and expresses 12S E1A lacking amino acids 38 ± 60 which is required for binding both Rb and p300 and is referred to as Ad-E1A-(dl CR1). (5) Ad5 dl 70-3 lacks both E1B and E1A genes and is referred to as Ad-E1A-(null). Adenoviral titers were determined and infections were carried out using an MOI of 50, as previously described (ElDeiry et al., 1993; Blagosklonny and El-Deiry, 1996) .
EMSA
The mouse anti-human p53 monoclonal antibody pAb421 (Ab1; Oncogene Science) was used to activate sequencespeci®c DNA-binding by p53 in electrophoretic mobility shift assays as previously described (Hupp et al., 1992) with the following modi®cations. A p53 binding site from the p21 promoter was used as the probe (5'-CAGGAA-CATGTCCCAACATGTTGAGC-3', site 1; El-Deiry et al., 1995) , and the following reaction conditions were used: 10% glycerol, 20 mM HEPES, pH 7.5, 25 mM KCl, 2 mM DTT, 2 mM MgCl 2 , 0.2% NP40, 1 mg poly(dI-dC), 0.3 mg pAb421, and 8 mg of nuclear extracts. Nuclear extracts were prepared at 24 h following adenoviral infection as previously described (Schreiber et al., 1989) , except that the cell lysis buer contained 1% antipain (Sigma), 1% leupeptin (Sigma), 1% pepstatin A (Sigma), 1% chymostatin (Sigma), and 0.1% AEBSF (Calbiochem).
Western and immunohistochemical analysis
Immunoblotting was performed using mouse anti-human p53 monoclonal pAb1801 (Ab2; Oncogene Science), mouse anti-human p21 WAF1/CIP1 monoclonal (EA10 clone; Ab1; Oncogene Science), mouse anti-human Rb monoclonal (LM95.1 clone; Ab5; Oncogene Science), mouse antihuman MDM2 monoclonal (IF2 clone; Ab-1; Oncogene Science), rabbit anti-human CDK2 polyclonal (M2 serum; Santa Cruz), mouse anti-adenoviral type 5 E1A monoclonal (M73; Ab1; Oncogene Science) antibodies as previously described (Zeng and El-Deiry, 1996) , except that 7.5% SDS-polyacrylamide gels were used for resolving alternative phosphorylated forms of Rb.
Immunohistochemical detection of p53 and p21 WAF1/CIP1
proteins was carried out using DO7 anti-human p53 monoclonal (Novacastra) and mouse anti-human p21 WAF1/ CIP1 monoclonal (EA10 clone; Ab1; Oncogene Science), at 24 h following adenoviral infection, as previously described (El-Deiry et al., 1995) . Some cells were also treated with chemotherapeutic agents (0.2 mg/ml adriamycin or 0.2 mM etoposide), added to the cultures at 5 h post-infection, as indicated in Figures 4, 5 and 7.
Thymidine incorporation
A total of 2610 4 H460 cells per well were seeded in 24 well plates. On the following day, adenoviral infections were carried out using an MOI of 50, as previously described (Blagosklonny and El-Deiry, 1996) . The chemotherapeutic agents adriamycin (®nal concentration 0.2 mg/ml) or etoposide (®nal concentration 0.2 mM) were added to the cell cultures 5 h following adenoviral infection. At 20 h post-infection, the cells were pulsed with 10 mCi of [ 3 H]thymidine (New England Nuclear) for 4 h, and radioactivity incorporated into newly synthesized DNA was quantitated as previously described (Wu and El-Deiry, 1996) . Missero et al., Genes & Dev. 10:3065 ± 3075, 1996 reported that the absence of p21 WAF1/CIP1 expression is associated with altered keratinocyte dierentiation and, when combined with the transforming ras oncogene, the development of undierentiated carcinoma. These results provide evidence that suppression of p21 expression in vivo may contribute to transformation and tumorigenesis, and are consistent with our hypothesis that suppression of p53-dependent (and/or -independent) expression of p21 by Adenovirus E1A may be important for its transforming activity.
Note added in proof
